Abstract:Abstract Background: Mutation in isocitrate dehydrogenase 1 (IDH1) occurs in > 70% of WHO grades II and III astrocytomas and oligodendrogliomas and secondary glioblastoma (GBM). The mutant enzyme catalyze the reduction of α-ketoglutaric acid to D-2-hydroxyglutaric acid, leading to cancer initiation. In this study, we examined the therapeutic efficacy of SYC-435 (1-hydroxypyridin-2-one), a newly developed mutant IDH1inhibitor, both in vitro and in vivo in IDH1 mutant gliomas as compared with IDH1 wild type GBMs. Methods: An established neurosphere line (BT142) of anaplastic oligoastrocytoma (AOA), and a patient-derived orthotopic xenograft (PDOX) model of recurrent AOA (IC-V0914AOA), and 2 PDOX models of GBM (IC-4687GBM and IC-3752GBM) were included. IDH1 mutations (R132H and R132C) were analyzed by pyrosequencing. To determine the in vitro antitumor activities, tumor cells were exposed to SYC-435 (0.02 to 20 µM) and examining for changes of cell proliferation every 3-4 days till day 13 by Cell Counting Kit-8 assay. For in vivo effects, orthotopic xenograft mouse models of IC-BT142AOA and IC-V0914AOA were treated with vehicle (as control), SYC-435 (i.p., 15 mg/kg/day x 28 days), temozolomide (TMZ, oral, 50 mg/kg/day x 5 days) + fractionated radiation (XRT, 2 Gy/day x 5 days) (as standard therapy), and combination of SYC-435 with standard therapy starting 2 weeks after intracranial tumor implantation. Animal survival times were analyzed by log rank analysis. Results: IDH1 R132H mutation (homozygous) was detected in BT142AOA neurosphere line and R132C mutation (mutant allele frequency 39-42%) in IC-V0914AOA xenograft cells, while the two GBM models (IC-4687GBM and IC-3752GBM) carried wild-type IDH1. Suppression of cell growth was observed in time- and dose-dependent manner by SYC-435, particularly at the IDH1 mutant models. At 0.5 µM, SYC-435 inhibited cell growth by 90% in BT142 and 60% in IC-V0914AOA cells, whereas in IDH wild-type GBMs only by 17% in IC-4687GBM and 19% in IC-3752GBM cells at day 13, indicating the high selectivity of SYC-435 of mutant over wild type IDH1. Systematic in vivo treatment with SYC-435 alone did not alter survival times in neither IC-BT142AOA nor IC-V0914AOA models when compared with the control group. Although standard therapy significantly prolonged animal survival times in both models (P<0.0005), combining SYC-435 with standard therapies further extended the median survival times from 106 days (in the standard therapy group) to 124 days (P<0.05) in IC-V0914AOA and exhibited similar trend in IC-BT142AOA. Conclusion: SYC-435 possesses antitumor effects that are highly selective in IDH1 mutant gliomas, and generated strong synergistic activities with standard therapies in vivo. Our data support the clinical testing of SYC-435 in patients with IDH1 mutant glioma. Citation Format: Mari Kogiso, Lin Qi, Huiyuan Zhang, Frank K. Braun, Yuchen Du, Yulun Huang, Holly Lindsay, Sibo Zhao, Sarah G. G. Injac, Zhen Liu, Patricia A. Baxter, Jack M. Su, Laszlo Perlaky, D. Williams Parsons, Murali Chintagumpala, Adekunle Adesina, Jialiang Wang, Yongcheng Song, Xiao-Nan Li. Mutant isocitrate dehydrogenase 1 (IDH1) inhibitor synergistically prolongs animal survival with standard therapies in patient-derived IDH1 mutant glioma xenograft mouse models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 4031. doi:10.1158/1538-7445.AM2017-4031

Relationship between efficacy of phase I/II drug ispinesib in medulloblastoma, molecular subtypes, and p53-mutant status.

Enhancing targeted therapy by combining PI3K and AKT inhibitors with or without cisplatin or vincristine in medulloblastoma cell lines in vitro

Depletion of kinesin motor KIF20A to target cell fate control suppresses medulloblastoma tumour growth

Antitumor Activity of NVP-BKM120--a Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on P53 Status of Glioma Cells.

DDIS-11. A CK1a ACTIVATOR PENETRATES THE BRAIN, AND SHOWS EFFICACY AGAINST DRUG-RESISTANT METASTATIC MEDULLOBLASTOMA

Csig-17. Adhesion Gpcr Bai1/Adgrb1 Can Block Igf1R-Mediated Growth Signalling, Increase Radiosensitivity And Augment Survival In Medulloblastoma

Multiplexed single-cell lineage tracing of mitotic kinesin inhibitor resistance in glioblastoma

EXTH-45. THERAPEUTIC EFFICACY OF MUTANT ISOCITRATE DEHYDROGENASE 1 (IDH1) INHIBITOR SYC-435 WITH STANDARD THERAPY IN PATIENT-DERIVED IDH1 MUTANT GLIOMA XENOGRAFT MOUSE MODELS

Combination of PARP and WEE1 inhibitors in vitro: Potential for use in the treatment of SHH medulloblastoma

Abstract 5341: Mechanisms driving resistance in Group 3 and recurrent/disseminated medulloblastoma

Cnsc-49. Elucidating Therapeutic Potential Of Usp1 Inhibition In Diffuse Midline Gliomas

The Kinesin KIF14 is Overexpressed in Medulloblastoma and Downregulation of KIF14 Suppressed Tumor Proliferation and Induced Apoptosis.

EMBR-32. INTEGRATED STRESS RESPONSE PLAYS A PRO-SURVIVAL ROLE IN MYC-DRIVEN MEDULLOBLASTOMA

Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action

Dddr-39. Pi3 Kinase And Checkpoint Inhibition: A Potentially Novel Therapeutic Strategy For Glioblastoma (Gbm)

PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma

EXTH-07. MUTANT ISOCITRATE DEHYDROGENASE 1 (IDH1) INHIBITOR SYC-435 SYNERGISTICALLY PROLONGS ANIMAL SURVIVAL WITH STANDARD THERAPIES IN PATIENT-DERIVED IDH1 MUTANT GLIOMA XENOGRAFT MOUSE MODELS

270 Inducing Neural Maturation and Increasing Survival in SHH Medulloblastoma Using EZH2 Inhibition in a Mouse Model

Synergistic anti-tumor efficacy of mutant isocitrate dehydrogenase 1 inhibitor SYC-435 with standard therapy in patient-derived xenograft mouse models of glioma

Abstract 4031: Mutant Isocitrate Dehydrogenase 1 (IDH1) Inhibitor Synergistically Prolongs Animal Survival with Standard Therapies in Patient-Derived IDH1 Mutant Glioma Xenograft Mouse Models

The p53 tumor suppressor protein protects against chemotherapeutic stress and apoptosis in human medulloblastoma cells